- International panel of renowned physicians, researchers,
veterinarians, engineers and academics
- Advisory Board to guide PharmaCielo's research and development
of special cannabinoids-based formulations and derived products
with therapeutic properties
TORONTO and RIONEGRO,
Colombia, April 9, 2019 /CNW/ - David Attard, Chief Executive Officer of
PharmaCielo Ltd. ("PharmaCielo" or the
"Company") (TSXV:PCLO), the Canadian parent of
Colombia's premier cultivator and
producer of medicinal-grade cannabis oil, PharmaCielo Colombia
Holdings S.A.S., is pleased to announce the appointment of the
Company's extended Medical and Scientific Advisory Board
(MSAB).
"Global adoption of medical cannabis therapy is nearing a
tipping point as acceptance by governments, healthcare
practitioners and the public reaches a critical mass," said
David Attard, Chief Executive
Officer with PharmaCielo. "With the guidance of our new
international Medical and Scientific Advisory Board, led by Dr.
Delon Human, PharmaCielo is well
positioned to become a global leader with medicinal cannabis
offerings backed by enhanced medical and scientific research
capabilities, advanced cultivation and extraction practices and the
development of innovative products."
The mandate of the MSAB is to enhance PharmaCielo's research and
product development plan, focused on the therapeutic properties of
cannabinoid-based formulations. The MSAB will also provide guidance
to PharmaCielo in safe and effective processes to use in the
development of medicinal, consumer and pet health products – while
adhering to stringent ethical research principles.
Dr. Delon Human, Global Head,
Health and Innovation with PharmaCielo and Chair of the MSAB,
noted, "The therapeutic potential of cannabinoids in helping to
reduce human suffering and illness and to enhance well-being is
enormous, and we have only scratched the surface of it. I believe
that the members of PharmaCielo's MSAB have the unique opportunity
to contribute to the development of the industry as a whole, by
adhering to the same high standards of research and product
identification used in related areas of medicinal research, as well
as by focusing attention on the patient community."
The extended MSAB, consists of world-renowned experts from the
medical, veterinarian, product R&D and academic fields,
including:
- Dr. Delon Human [Switzerland], Global Head of Health
and Innovation with PharmaCielo and Chair of the MSAB, is a
published author, international lecturer and health care consultant
specializing in global health strategy, corporate and product
transformation, harm reduction and health communication. As Chair
of PharmaCielo's MSAB, Dr. Human will lead the overall health
strategy, oversee product-based R&D, engage with key
stakeholders such as the United Nations (UN) and World Health
Organization (WHO), and ensure necessary regulatory standards for
tracking of the Company's products within the global distribution
network are maintained.
- Dr. Nadia Crosignani [Uruguay] is a veterinarian, working as a
professor and researcher in the Faculty of Veterinary Medicine at
the University of the Republic of Uruguay (UdelaR). She is also a member of the
Nucleus of Cannabis Research in UdelaR. As a PharmaCielo MSAB
member, Dr. Crosignani will bring her research experience and
expertise in analgesia and veterinary medicine to support the
Company in pet health product development.
- Dr. Konstantinos Farsalinos [Greece], a cardiologist and researcher at
the Onassis Cardiac Surgery Centre, Department of Pharmacology,
University of Patras, is recognized as a global expert in tobacco
harm reduction and product development. As a MSAB member, Dr.
Farsalinos will bring his vast knowledge and expertise in
ingredient and emission chemical analysis, as well as draw from his
research on novel forms of medicinal cannabis and its
administration using metered dose devices.
- Prof. Gerard Madlambayan
[United States], a professor
of biological sciences at Oakland
University in Rochester,
Michigan, is recognized for his translational research
efforts in stem-cell therapies and drug discovery for treating
cancer. Professor Madlambayan's background in biomedical
engineering will support PharmaCielo in the development of
world-class, GMP-certified laboratories and manufacturing
facilities as well as provide assistance in all aspects of
product-based R&D.
- Dr. Anders Milton
[Sweden], the former CEO and
secretary general of the Swedish Medical Association, chairman of
the council of the World Medical Association and chairman of the
Swedish Red Cross, specializes in ethics of medical practice and
safe healthcare, critical elements in any company focused on
developing products for medicinal use. As part of the MSAB, Dr.
Milton will leverage his experience as a public health leader to
bridge the gap between policy, science and business
development.
- Prof. Riccardo Polosa
[Italy], professor of internal
medicine and head of the Institute of Internal and Emergency
Medicine at the University of Catania in Sicily, where he founded and currently
supervises the Centre for Tobacco Research. Professor Polosa brings
to PharmaCielo's MSAB unparalleled expertise in the development of
various forms of inhalable, ingestible and oral drugs, as well as
an extensive track record in consumer behaviour, clinical trials
and post-market surveillance.
- Prof. Solomon Rataemane [South
Africa], head of the Department of Psychiatry at the
University of Limpopo in Pretoria,
brings a vast research background in child psychiatry, mood
disorders and addiction medicine. He is the former chairperson of
the Central Drug Authority of South
Africa and serves as the general secretary of the World
Association for Psychosocial Rehabilitation. As a MSAB member,
Professor Rataemane will provide counsel on youth usage of
psychoactive substances and contribute his expertise to product
R&D of cannabinoid-based treatments for mental health
conditions.
- Prof. David Richardson
[United Kingdom] is head of a
speciality consulting firm in nutrition and food sciences and holds
visiting professorships at the School of Chemistry, Food and
Pharmacy, University of Reading. He is also the former Group Chief
Scientist for Nestle UK. As a MSAB member, Professor Richardson
will support PharmaCielo in developing a research agenda for
cannabinoid-based nutraceuticals, and guide the regulatory path to
accreditation, consumer safety, care and support.
About PharmaCielo
PharmaCielo Ltd. (TSXV:PCLO) is a
global company, headquartered in Canada, with a focus on ethical and
sustainable processing and supplying of all natural,
medicinal-grade cannabis oil extracts and related products to large
channel distributors. PharmaCielo's principal (and wholly owned)
subsidiary is PharmaCielo Colombia Holdings S.A.S., headquartered
at its nursery and propagation centre located in Rionegro,
Colombia.
The boards of directors and executive teams of both PharmaCielo
and PharmaCielo Colombia Holdings are comprised of a diversely
talented group of international business executives and specialists
with relevant and varied expertise. PharmaCielo recognized the
significant role that Colombia's
ideal location will play in building a sustainable business in the
medical cannabis industry, and the Company, together with its
directors and executives, is executing on a business plan focused
on supplying the international marketplace.
Forward-Looking Statements
This press release contains forward-looking statements.
Forward-looking statements can be identified by the use of words
such as, "expects", "is expected", "intends", "believes", or
variations of such words and phrases or state that certain actions,
events or results "may" or "will" be taken, occur or be achieved.
Forward-looking statements are based on assumptions, including with
respect to PharmaCielo's planned products, and the ability to
execute its business plan that management believes are reasonable
in the circumstances, but the actual results, performance or
achievements of PharmaCielo's business may be materially different
from any future results, performance or achievements expressed or
implied by any forward-looking statements. Forward-looking
statements can be affected by known and unknown risks,
uncertainties and other factors, including, but not limited to, the
equity markets generally, risks associated with early stage
companies, risks associated with the regulation of cannabis and
cannabinoid derivatives, failure to obtain necessary TSXV approval,
competition for PharmaCielo's planned products, risks associated
with operating in Colombia, and
currency exchange risk. Accordingly, readers should not place undue
reliance on forward-looking statements.
Except as required by law, PharmaCielo undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
SOURCE PharmaCielo Ltd.